Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Gladiator HA Coated Modular Femoral Stems

MicroPort Orthopedics Inc.154 enrolled

Overview

MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) and resurfacing components marketed in the European Union (EU). These types of studies are required by regulatory authorities for all THA and resurfacing devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in the EU. This study has been designed in accordance with the medial device directives (MEDDEV) 2.12/2 rev 2.

Study Type

OBSERVATIONAL

Enrollment

154

Conditions

Joint Disease

Interventions

PROFEMUR® Gladiator HA Coated Modular Femoral StemDEVICE

Total Hip Arthroplasty (THA) using PROFEMUR® Gladiator HA Coated Modular Femoral Stem

Eligibility

Sex: ALLMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject has undergone primary THA for any of the following: * Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, or painful hip dysplasia; * Inflammatory degenerative joint disease such as rheumatoid arthritis; or * Correction of functional deformity * Subject is implanted with the specified combination of components * Subject is willing and able to complete required study visits or assessments Previously implanted bilateral subjects can have both THAs enrolled in the study provided: 1) the specified combination of components were implanted in both, 2) all other aspects of the Inclusion/Exclusion Criteria are satisfied, 3) enrollment does not exceed the subject count specified in the Investigator Agreement, and 4) the subject agrees to a second Informed Consent document specific to the second THA. Prospective enrollment of a previously unimplanted hip is not permitted in this study. Exclusion Criteria: * Subjects skeletally immature (less than 21 years of age) at time of primary THA surgery * Subjects currently enrolled in another clinical study which could affect the endpoints of this protocol * Subjects unwilling to sign the Informed Consent document * Subjects with substance abuse issues * Subjects who are incarcerated

Locations (1)

Medisch Centrum Latem (outpatient clinic associated with AZ Maria-Middelares)

Sint-Martens-Latem, Flanders, Belgium

Outcomes

Primary Outcomes

Component Survivorship

The primary objective of this study is to estimate survivorship of all components at specified intervals out to 10 years follow-up.

Time frame: 10 years post-operative

Secondary Outcomes

Patient functional outcomes (hip specific)

To characterize total functional scores, as assessed by Hip disability and Osteoarthritis Outcome Scores (HOOS)

Time frame: 5 months, 1, 2, 5, 7, and 10 years beginning with first available follow-up interval

Patient functional outcomes (quality of life)

To characterize total functional scores, as assessed by EQ-5D-3L scores

Time frame: 5 months, 1, 2, 5, 7, and 10 years beginning with first available follow-up interval

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.